- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00334724
Home Blood Pressure-guided Antihypertensive Intervention for Elderly (HBP-GUIDE) Study
December 28, 2015 updated by: Kyoto University, Graduate School of Medicine
The purpose of this study is to determine whether blood pressure control by home blood pressure monitoring exerts beneficial cardioprotective effects rather than by clinic blood pressure monitoring in elderly patients.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Home blood pressure (BP) measurement has been reported to be closely correlated with target organ damage and appears to be a prognostic indicator with respect to cardiovascular mortality and cardiovascular events.
However, whether BP control by home BP monitoring exerts cardioprotective effects rather than by clinic BP monitoring in elderly patients remains unknown.
In this study, a total of 500 elderly patients diagnosed with essential hypertension will be randomly divided into 2 groups; target BP level, home SBP <135 mmHg and home DBP <85 mmHg (home BP control group), clinic SBP <140 mmHg and clinic DBP <90 mmHg (clinic BP control group).
Olmesartan at doses of 20 mg/day will be administered and increased up to 40 mg, if antihypertensive effect is inadequate.
Study visits will be made bimonthly for at least 1 year.
The antihypertensive and cardioprotective effects including systemic levels of C-reactive protein and inflammatory cytokines, and arterial stiffness will be compared between the two groups.
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kyoto, Japan, 602-8566
- Division of Internal Medicine, Kyoto Prefectural University of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years to 80 years (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Outpatients aged over 65 years and less than 80 years
- Patients with a stable seated systolic blood pressure of ≥ 140 mmHg or diastolic blood pressure of ≥ 90 mmHg at two visits within 8 weeks
- Patients with a stable seated systolic blood pressure of ≥ 135 mmHg or diastolic blood pressure of ≥ 85 mmHg at home (home blood pressure is measured every morning within 1 h of waking, and defined as the mean of 3 days measurement within 8 weeks)
Exclusion Criteria:
- Patients with secondary hypertension or malignant hypertension
- Patients with a stable seated systolic pressure of ≥ 180 mmHg or diastolic pressure of ≥ 110 mmHg
- Patients with renal dysfunction with a serum creatinine level of ≥ 2 mg/dl
- Patients with liver dysfunction
- Patients with a history of hypersensitivity to angiotensin II receptor blockade
- Patients with a history of myocardial infarction within 6 months prior to enrolment in the study
- Patients who underwent coronary arterioplasty within 6 months prior to enrolment in the study or patients who will undergo coronary arterioplasty within 6 months after entry
- Patients with heart failure
- Patients with a history of cerebrovascular disorder
- Other patients who are judged to be inappropriate for the study by the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Home blood pressure group
|
Blood pressure controlled based on home blood pressure measurement
|
Active Comparator: 2
Office blood pressure group
|
Blood pressure controlled based on office blood pressure measurement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Home blood pressure
Time Frame: one year
|
one year
|
Office blood pressure
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pulse wave velocity
Time Frame: one year
|
one year
|
high sensitive C-reactive protein
Time Frame: one year
|
one year
|
Interleukin-6
Time Frame: one year
|
one year
|
urine microalbumin
Time Frame: one year
|
one year
|
Plasminogen activator inhibitor activity
Time Frame: one year
|
one year
|
B-type natriuretic peptide
Time Frame: one year
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Hiroaki Matsubara, MD, PhD, Professor of Medicine, Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
November 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
June 7, 2006
First Submitted That Met QC Criteria
June 7, 2006
First Posted (Estimate)
June 8, 2006
Study Record Updates
Last Update Posted (Estimate)
December 29, 2015
Last Update Submitted That Met QC Criteria
December 28, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-136
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Home blood pressure measurement
-
Jichi Medical UniversityCompleted
-
Kaiser PermanentePatient-Centered Outcomes Research InstituteCompleted
-
Hospital Clinic of BarcelonaRecruitingArterial Hypertension | Frailty Syndrome | Heart Failure With Preserved Ejection Fraction | Comorbidities and Coexisting ConditionsSpain
-
University of Maryland, BaltimoreTerminated
-
Murdoch Childrens Research InstituteCompletedHypertension | Blood Pressure | Neurofibromatosis 1Australia
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI); Columbia UniversityCompletedBlood PressureUnited States
-
Consorci d'Atenció Primària de Salut de l'EixampleInstituto de Salud Carlos IIICompleted
-
Accumbo ABUniversity Hospital, LinkoepingCompleted
-
Renaissance University Ugbawka, EnuguEnrolling by invitation